

**Freedom of Information Act 2000 - Request Reference FoI/23/019**  
**Multiple Sclerosis Treatment and Diagnosis**

**1. How many patients has your trust/health board treated in the past 6 months (for any disease) with the following drugs:**

Aubagio (teriflunomide)	7
Avonex (interferon beta-1a)	0
Betaferon (interferon beta-1b)	0
Brabio (glatiramer acetate)	4
Copaxone (glatiramer acetate)	0
Extavia (beta interferon-1b)	0
Gilenya (fingolimod)	49
Lemtrada (alemtuzumab)	23
Kesimpta (ofatumumab)	10
Mavenclad (cladribine)	13
Mayzent (siponimod)	25
Ocrevus (ocrelizumab)	112
Plegridy (peginterferon beta-1a)	7
Ponvory (ponesimod)	0
Rebif (beta interferon-1a)	0
Tecfidera (dimethyl fumarate)	134
Tysabri (natalizumab)	89
Tysabri (natalizumab) pre-filled syringes ONLY	77
Vumerity (diroximel fumarate)	4
Zeposia (ozanimod)	1

**2. How many hospital patients (inpatients or outpatients) currently have a diagnosis for the following conditions:**

- **Multiple sclerosis (any type)**
- **Relapsing remitting multiple sclerosis (RRMS)**
- **Primary progressive multiple sclerosis (PPMS)**
- **Secondary progressive multiple sclerosis (SPMS)**

Period: 1 Aug 2022 to 31 Jan 2023

Distinct patients in period coded with diagnosis of MS: 277

NB: Based on MS diagnosis codes in any diagnosis position in all Episodes. Based on Coding as of:  
7 Feb 2023